Enzo Biochem
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 43 [Q3] → 44 (+1) [Q4]
1.68% more ownership
Funds ownership: 24.58% [Q3] → 26.27% (+1.68%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
31% less capital invested
Capital invested by funds: $14.2M [Q3] → $9.8M (-$4.37M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ENZ.
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”).
Neutral
GlobeNewsWire
2 weeks ago
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss.
Neutral
GlobeNewsWire
2 months ago
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) its 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) the average closing price of the Company's Common Stock (the “Common Stock”) was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock.
Negative
Zacks Investment Research
3 months ago
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market.
Neutral
GlobeNewsWire
3 months ago
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update
FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024.
Positive
Zacks Investment Research
5 months ago
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
Neutral
GlobeNewsWire
5 months ago
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock.
Negative
Reuters
7 months ago
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Positive
Seeking Alpha
8 months ago
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.
Negative
Zacks Investment Research
9 months ago
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Charts implemented using Lightweight Charts™